Eur Rev Med Pharmacol Sci 2022; 26 (9): 3083-3090

DOI: 10.26355/eurrev_202205_28725

MiR-572 promotes the development of non-small cell lung cancer by targeting KLF2

B. Sun, J. Zhao, Z.-Y. Shao

Department of Thoracic Surgery, Jining No. 1 People’s Hospital, Jining, China. 13515313381@139.com


OBJECTIVE: The aim of this study was to uncover the role of miR-572 in regulating proliferative and migratory abilities in non-small cell lung cancer (NSCLC) and the possible mechanism.

PATIENTS AND METHODS: Expression levels of miR-572 in 46 matched NSCLC and paracancerous samples were detected. The relationship between miR-572 level and clinical features of NSCLC was analyzed. Subsequently, the regulatory effects of miR-572 on proliferative and migratory abilities in lung cancer cells were assessed by functional experiments. Finally, the downstream genes of miR-572 were tested by luciferase assay, and their functions in the development of NSCLC were finally explored by rescue experiments.

RESULTS: It was found that miR-572 was upregulated in NSCLC samples. High level of miR-572 predicted high rates of lymphatic and distant metastases, as well as poor prognosis in NSCLC. Besides, the knockdown of miR-572 suppressed proliferative and migratory abilities in A549 and SPC-A1 cells. KLF2 was identified to be the downstream gene of miR-572, which was involved in the regulation of NSCLC phenotypes influenced by miR-572.

CONCLUSIONS: MiR-572 is closely linked to metastasis and prognosis in NSCLC patients, and it promotes the malignant development of NSCLC via targeting KLF2.

Free PDF Download

To cite this article

B. Sun, J. Zhao, Z.-Y. Shao
MiR-572 promotes the development of non-small cell lung cancer by targeting KLF2

Eur Rev Med Pharmacol Sci
Year: 2022
Vol. 26 - N. 9
Pages: 3083-3090
DOI: 10.26355/eurrev_202205_28725